Skip to Content

ImmuneRegen BioSciences, Inc. Demonstrates That Viprovex Is a Potential Treatment for Avian and Other Influenzas

SCOTTSDALE, Ariz., January 09, 2007 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. , today announced results from tests conducted using Viprovex(TM), its proprietary compound, in a severe influenza treatment study. Tests evaluating ImmuneRegen's Viprovex(TM) as a measure in the possible treatment of influenza virus infection were conducted at Virion Systems, Inc. (VSI), a Maryland biotechnology corporation. Influenza studies were performed using a cotton rat (Sigmodon hispidus) model system with the influenza A/Wuhan/359/95 (H3N2), a robust, peer-reviewed model system for studying human influenza.

Management believes that preliminary results of Viprovex treatment of cotton rats infected with the H3N2/Wuhan human influenza virus provided indications that Viprovex may have positive effects on enhancing immunity against influenza infection and supports ongoing development of Viprovex as a potential treatment for seasonal influenza.

Viprovex treatment reduced nasal and lung titers one- to two- logs (90+ %) compared to infected but untreated controls. In addition, treated animals appeared to lose less weight than untreated infected animals and appeared to regain normal body weight more rapidly. Additionally, Viprovex treated animals appeared to have less change in body temperature then untreated animals.

Company officials believe that the preliminary data suggests that Viprovex could have positive effects in the treatment of influenza infection perhaps through the modulation of cytokine activation and in the enhancement of innate immunity to influenza. Additional studies are presently underway in this and other influenza model systems to confirm and expand these results.

About Virion Systems, Inc.

Virion Systems, Inc. is a Maryland biotechnology corporation focused on the prevention and treatment of infectious diseases, particularly those involving infants and children. Its core technology is the use of the cotton rat as an animal model of human infectious diseases. VSI performs contract research for academic and commercial groups, centered around the use of the cotton rat. In addition to research on prevention and treatment of infectious diseases, VSI also conducts contract research involving the use of adenoviruses as vectors for genetic therapy, as the cotton rat is the only small animal permissive for human adenoviruses.

About ImmuneRegen BioSciences, Inc.

IR BioSciences Holdings Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from modified Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system.

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre- clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-QSB for the three months ended September 30, 2006 and on Form 10-KSB for the twelve months ended December 31, 2005 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward- looking statements.

Posted: January 2007